The relevance to human health and disease is suggested by the correlation between serum S100A8/S100A9 (the associated DAMPs) and the incidence of CAD in a subset of T1D patients from the Pittsburgh EDC study, highlighting the potential importance of glucose control and lipid-lowering therapy as strategies to promote regression of atherosclerosis in diabetics and also suggesting a number of therapeutic targets, including disruption of the S100A8/S100A9-RAGE signaling axis (Nagareddy et al., 2013). This evidence concerns the gene S100A9 and type 1 diabetes mellitus.